Fundraising FoxThird Rock Ventures — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.
BiotechHealthtech
Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in
Co-investorsBain Capital Life SciencesGV (Google Ventures)Biotechnology Value FundThe Engine Ventures
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsLifeSci Venture PartnersNextech InvestAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.